|Cyclacel Pharmaceuticals, Inc.|
200 Connell Drive
United States - Map
|Full Time Employees:||18|
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The companys oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The companys non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
|Mr. Spiro Rombotis ,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Paul McBarron ,
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and Exec. Director
|Dr. Judy H. Chiao M.D.,
Chief Medical Officer and VP of Clinical Devel. & Regulatory Affairs
|Prof. David Glover Ph.D., FRS FRSE,
|Dr. Susan Davis Ph.D.,
Director of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|